Patient-Specific Stem Cells and Personalized Gene Therapy
Patients’ own cells transformed into model for studying disease and developing potential treatment
NEW YORK, NY (July 10, 2014) — Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.
Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
“The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient’s genetic deficiency provides yet another tool for advancing the field of personalized medicine,” said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.
While RP can begin during infancy, the first symptoms typically emerge in early adulthood, starting with night blindness. As the disease progresses, affected individuals lose peripheral vision. In later stages, RP destroys photoreceptors in the macula, which is responsible for fine central vision. RP is estimated to affect at least 75,000 people in the United States and 1.5 million worldwide.
More than 60 different genes have been linked to RP, making it difficult to develop models to study the disease. Animal models, though useful, have significant limitations because of interspecies differences. Researchers also use human retinal cells from eye banks to study RP. As these cells reflect the end stage of the disease process, however, they reveal little about how the disease develops. There are no human tissue culture models of RP, as it would dangerous to harvest retinal cells from patients. Finally, human embryonic stem cells could be useful in RP research, but they are fraught with ethical, legal, and technical issues.
The use of iPS technology offers a way around these limitations and concerns. Researchers can induce the patient’s own skin cells to revert to a more basic, embryonic stem cell–like state. Such cells are “pluripotent,” meaning that they can be transformed into specialized cells of various types.
In the current study, the CUMC team used iPS technology to transform skin cells taken from two RP patients—each with a different MFRP mutation—into retinal cells, creating patient-specific models for studying the disease and testing potential therapies.
By analyzing these cells, the researchers found that the primary effect of MFRP mutations is to disrupt the regulation of actin, the protein that makes up the cytoskeleton, the scaffolding that gives the cell its structural integrity. “Normally, the cytoskeleton looks like a series of connected hexagons,” said Dr. Tsang. “If a cell loses this structure, it loses its ability to function.”
The researchers also found that MFRP works in tandem with another gene, CTRP5, and that a balance between the two genes is required for normal actin regulation.
In the next phase of the study, the CUMC team used adeno-associated viruses (AAVs) to introduce normal copies of MFRP into the iPS-derived retinal cells, successfully restoring the cells’ function. The researchers also used gene therapy to “rescue” mice with RP due to MFRP mutations. According to Dr. Tsang, the mice showed long-term improvement in visual function and restoration of photoreceptor numbers.
“This study provides both in vitro and in vivo evidence that vision loss caused by MFRP mutations could potentially be treated through AAV gene therapy,” said coauthor Dieter Egli, PhD, an assistant professor of developmental cell biology (in pediatrics) at CUMC, who is also affiliated with the New York Stem Cell Foundation.
Dr. Tsang thinks this approach could also be used to study other forms of RP. “Through genome-sequencing studies, hundreds of novel genetic spelling mistakes have been associated with RP,” he said. “But until now, we’ve had very few ways to find out whether these actually cause the disease. In principle, iPS cells can help us determine whether these genes do, in fact, cause RP, understand their function, and, ultimately, develop personalized treatments.”
The paper is titled, “Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein (MFRP) defects.” The other contributors are Yao Li (CUMC), Wen-Hsuan Wu (CUMC), Chun-Wei Hsu (CUMC), Huy V. Nguyen (CUMC), Yi-Ting Tsai (CUMC), Lawrence Chan (CUMC), Takayuki Nagasaki (CUMC), Irene H. Maumenee (Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL), Lawrence A. Yannuzzi (CUMC), Quan V. Hoang (CUMC), and Haiqing Hua (CUMC and NYSCF, New York, NY).
The authors declare no financial or other conflicts of interests.
The study was supported by grants from the National Institute of Health (5P30EY019007, 5P30CA013696, R01EY018213), Research to Prevent Blindness, the Tistou and Charlotte Kerstan Foundation, the Barbara and Donald Jonas Laboratory, the Schneeweiss Stem Cell Fund, New York State (N09G-302, N13G-275), a Foundation Fighting Blindness New York Regional Research Center Grant (C-NY05-0705-0312), the Joel Hoffman Fund, the Gale and Richard Siegel Stem Cell Fund, the Laszlo Bito and Olivia Carino Foundation, the Irma T. Hirschl Charitable Trust, the Bernard and Anne Spitzer Stem Cell Fund, the Professor Gertrude Rothschild Stem Cell Foundation, and the Gebroe Family Foundation.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.